Supplemental Figure 2: TTX-R Na
+ current densities trend toward enhancement in mice with chronic morphine exposure (related to Figure 4) . Non-normalized current-voltage (I-V) relationships of TTX-R Na + channels are shown at baseline (black) and following acute morphine challenge (3 μM, red) . Current densities demonstrate a trend toward enhancement in mice chronic morphine exposure (MP) compared to placebo (PP). However, this effect was not statistically significant in this study. PP+SAL (N=7,n=7), PP+VAN (N=4, n=6) , MP+SAL (N=7, n=9) , MP+VAN (N=5, n=7) , analyzed by two-way repeated-measures ANOVA with Bonferroni post-hoc analysis; data expressed as mean ± SEM.
Supplemental Figure 3: The time constant of TTX-R Na
+ channel inactivation is not affected by acute morphine challenge (related to Figure 6 ). Inactivation time constants (τinactiv) of TTX-R Na + channels at baseline (black) and following acute morphine challenge (3 μM, red). Values were estimated by fitting a monoexponential function to the falling phase of the current traces at various step potentials. While a general trend toward reduction of τinactiv with acute morphine challenge (3 μM) is noted, no significant modulation was detected in any cohort. PP+SAL (N=7,n=7), PP+VAN (N=4, n=6) , MP+SAL (N=7,n=9), MP+VAN (N=5, n=7) , analyzed by two-way repeated-measures ANOVA with Bonferroni post-hoc analysis; data expressed as mean ± SEM. Group sizes. The sample size "N" for each experimental condition is provided in the results and figure legends. These values represent independent observations, not replicates. For patch-clamp experiments, "N" represents the total number of animals, and "n" the total number of cells.
Supplemental
Randomization. All animals were randomly divided into control and treatment groups.
Oral vancomycin treatment. Vancomycin (Sigma-Aldrich, St. Louis, MO) was administered at 10 mg/kg via oral gavage every 12 hours for 10 days, unless otherwise indicated. Control mice received saline gavage treatments of identical volume and frequency. For treatment duration studies, vancomycin was administered at 10 mg/kg via oral gavage every 12 hours for 5, 10, or 15 days. For all groups, morphine pellets were implanted 5 days prior to the final testing day.
Chronic morphine treatment. For chronic morphine administration, a 75 mg morphine or placebo pellet was implanted subcutaneously on the dorsum. Mice were anesthetized with 2.5% isoflurane before shaving the hair from the base of the neck. The skin was cleansed with 10% povidone iodine (General Medical Corp., Walnut, CA) and rinsed with alcohol before making a 1 cm horizontal incision at the base of the neck. The subcutaneous space was opened by insertion of a sterile glass rod toward the dorsal flanks. The pellet was inserted in the space before closing the site with Clay Adams Brand, MikRon AutoClip 9-mm Wound Clips (Becton Dickinson, Franklin Lakes, NJ) and cleansing the surgical site again with 10% povidone iodine. Maintenance of a stringent aseptic surgical field minimized any potential contamination of the pellet, incision, and subcutaneous space. The animals were allowed to recover in their home cages where they remained throughout the experiment.
Tail-immersion assay.
To test nociceptive responses, the tail-immersion assay was used in this study. Mice were gently detained in a cloth, and the distal 1/3 of the tail immersed in a water bath at 52°C. The latency to tail-flick was recorded, with a maximum latency of 10 sec (to prevent tissue damage). Acute morphine challenge (10 mg/kg, s.c.) was administered 25 min prior to testing. DRG isolation. Dorsal root ganglia were harvested from spinal levels supplying the distal alimentary canal (L5-S1; modified from Malin et al., 2007) and immediately placed in cold (4 °C) Hanks' balanced salt solution (HBSS; ThermoFisher Scientific, Waltham, MA). Ganglia were incubated (37°C) for 18 min in HBSS with 15 U/mL papain, washed, and incubated for 1 hour in HBSS with 1.5 mg/mL Clostridium histolyticum collagenase. Tissues were gently triturated and centrifuged for 5 min at 1,000 rpm. The supernatant was decanted, and cells resuspended in neurobasal A medium containing 1% fetal bovine serum (FBS), 1x B-27 supplement, 10 ng/mL glial cell line-derived neurotropic factor (GDNF, Neuromics, Edina, MN), 2 mM L-glutamine (ThermoFisher Scientific, Waltham, MA), and penicillin/streptomycin/amphotericin B. The suspension was plated on poly-D-lysine-and laminin-coated coverslips (ThermoFisher Scientific, Waltham, MA) and incubated (37°C) for 24 hr. Electrophysiology. Coverslips were transported to an inverted microscope and continuously superfused with external physiologic saline solution (PSS) at room temperature (20°C). A GΩ seal was achieved via pulled (Model P-97 Flaming/Brown Micropipette Puller, Sutter Instruments, CA) and fire-polished (2-4 MΩ) borosilicate glass capillaries (World Precision Instruments, Sarasota, FL) filled with internal PSS. Standard patch-clamp techniques were performed using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA), Digidata 1440A digitizer, and associated Clampex and Clampfit 10.2 software. All records were performed in whole-cell configuration with digitization at 10 kHz sampling frequency and 5 kHz low-pass Bessel filtering. Only low capacitance (< 30 pF) neurons with healthy morphology and resting membrane potentials more negative than -40 mV were selected for analysis. These cells have been demonstrated to possess characteristics associated with nociceptors, including C and Aδ fiber types, capsaicin sensitivity, long action potential duration, and tetrodotoxin-resistant action potentials (Gold, Shuster and Levine, 1996; Yoshimura and de Groat, 1999; Moore et al., 2002; Beyak et al., 2004; Jin et al., 2013) . All recordings were performed 5 min after breakthrough to allow dialysis of internal solution. Cells displaying instability of seal resistance, variable access resistance, or rundown of currents were excluded from the study. No leak subtraction techniques were employed.
For current-clamp experiments, external PSS contained (in mM) 135 NaCl, 5.4 KCl, 0.33 NaH2PO4, 5 HEPES, 1 MgCl2, 2 CaCl2, and 5 glucose (pH adjusted to 7.4 with 1 M NaOH). Internal PSS contained (in mM) 100 L-aspartic acid (K salt), 30 KCl, 4.5 Na2ATP, 1 MgCl2, 10 HEPES, 0.1 EGTA, and 0.5 NaGTP (pH adjusted to 7.2 with 3 M KOH). The observed liquid-junction potential of -12.0 mV was not corrected. Current-clamp step protocols consisting of a 0 nA resting current and 0.03 nA steps from −0.03 nA were employed to assess passive and active cell properties. A short (5 ms) pulse was ultilized for assessment of threshold potential and rheobase. A long (100 ms) pulse was utilized to assess the number of action potentials at double rheobase. Taking the derivative of the voltage with respect to time (dV/dt), threshold potentials were defined as the voltage at which dV/dt significantly deviated from zero in the course of an action potential uprise. Records were conducted at 1 min intervals for 10 min. The maximum effect of morphine was recorded for each cell.
For voltage-clamp experiments, external solution supplemented with 1 μM TTX contained (in mM) 70 NaCl, 65 NMDG, 5.4 CsCl, 0.33 NaH2PO4, 5 HEPES, 2.95 MgCl2, 0.05 CaCl2, and 5 glucose (pH adjusted to 7.4 with concentrated HCl). Internal PSS contained (in mM) 100 CsF, 30 CsCl, 4.5 Na2ATP, 1 MgCl2, 10 HEPES, 6 EGTA, and 0.5 NaGTP (pH adjusted to 7.2 with 1 M CsOH). The calculated liquid-junction potential of -10.2 mV was not corrected. To assess the voltage-dependence of activation and steady-state inactivation, a double-pulse protocol was employed. A 50 ms variable conditioning pulse was applied in 5 mV steps from -100 to +50 mV. This was followed by a brief (1 ms) interval at -100 mV, then a 50 ms test pulse at 0 mV. Voltage-clamp errors were minimized by 1) selecting cells with <10 MΩ series resistance, 2) performing 75-85% series resistance compensation, 3) reducing external [Na + ] to avoid saturation of the amplifier and diminish current-dependent errors of the clamp voltage, and 4) choosing small, spherical neurons with few projections to reduce space clamp errors. When removed, external Na + was replaced by the non-permeable organic monovalent cation NMDG. Cells demonstrating instability of or large deviations from the theoretical equilibrium potential of Na + (50.6 mV at 20°C) were excluded from the study. The equilibrium potentials observed in I-V curves are notably all near the value predicted by the Nernst equation (when corrected for the liquid-junction potential TTX-R Na + current-voltage (I-V) relationships were constructed using peak inward currents elicited at each potential of the conditioning pulse. Where indicted, data are presented as either raw current density (pA/pF) or values normalized to the maximum inward current density between baseline and acute morphine challenge. To map voltage-dependence of activation, observed current densities were transformed to relative conductances (G/Gmax). Observed current densities were taken as a fraction of expected current densities under conditions of maximum conductance by extrapolating the Ohmic portion of the I-V curve. The resulting values were fit with a single Boltzmann function G/Gmax = 1/(1+exp[V-V1/2]/k), where G/Gmax is relative conductance, V is command potential, V1/2 is the potential of half-maximum activation, and k is the slope factor. For steady-state inactivation studies, the relative peak current density (I/Imax) elicited by the test pulse was plotted as a function of the conditioning pulse potential and fit with a single Boltzmann function. Inactivation time constants (τinactiv) were then estimated by fitting a monoexponential function to the falling phase of the current traces.
